Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
151
resultados
Última actualización
14/07/2026 [07:49:00]
Resultados 50 a 75 de 151
Resumen de: WO2026130307A1
Provided are small-fragment RNA derived from a circular RNA and the use thereof in the treatment of diabetic vascular diseases. The nucleotide sequence of the small-fragment RNA is CUAGCCGAAUGUUAAAAAAU. The provided small-fragment RNA has the effects of well protecting and maintaining the biological functions of vascular endothelial cells, has good structural stability, has a long half-life in vivo, and has the advantages of low effective concentration, high biological safety, etc. The provided small-fragment RNA has good application potentials in the field of clinical nucleic acid drug development, and provides a new idea for the treatment of chronic progressive vascular lesions caused by diabetes.
Resumen de: US20260174803A1
0000 The present disclosure provides novel methods for increasing β-cell viability in islets by delivering RLIP76 polypeptides or GSTA4 polypeptides, or a combination thereof; or RLIP76 polynucleotides or GSTA4 polynucleotides, or a combination thereof, to the islets. The disclosure also provides novel methods for treating a disease or condition in a subject, such as type 1 diabetes mellitus, by delivering RLIP76 polypeptides or GSTA4 polypeptides, or a combination thereof; or RLIP76 polynucleotides or GSTA4 polynucleotides, or a combination thereof, to islets and transplanting the islets into the subject to treat the disease or condition. Kits and compositions including RLIP76 polypeptides or GSTA4 polypeptides, or a combination thereof; or RLIP76 polynucleotides or GSTA4 polynucleotides, or a combination thereof, are also provided to increase β-cell viability.
Resumen de: US20260174360A1
Described herein are variations of an analyte monitoring system, including an analyte monitoring device. For example, an analyte monitoring device may include an implantable microneedle array for use in measuring one or more analytes (e.g., glucose), such as in a continuous manner. Each microneedle of the microneedle array may include a microneedle body, an electrode material on the microneedle body, a biorecognition layer on the electrode material, a diffusion-limiting layer on the biorecognition layer, an interferent blocking agent, and/or an attachment enhancer between the biorecognition layer and the diffusion-limiting layer, where the interferent blocking agent and the attachment enhancer are configured to improve sensor sensitivity variability.
Resumen de: US20260177565A1
0000 An agent is for inhibiting glucose uptake into red blood cells and a blood collection tube suppresses glucose concentration decrease. The agent for inhibiting glucose uptake into red blood cells includes inosine as an active ingredient. The inhibition agent can be used for suppressing a decrease in glucose concentration of whole blood collected in a blood collection tube. The blood collection tube includes inosine in an internal space. The blood collection tube can be used to measure glucose concentration in blood. The blood collection tube can further include a glycolysis inhibitor.
Resumen de: WO2026137021A2
A cancer screening method takes advantage of the Warburg Effect to provide an early detection method and system. The cancer screening method includes administering a glucose solution, such as a C-13 glucose solution, measuring a metabolized lactate level in the blood of the individual after a period of time following the administration of the glucose solution, and comparing the measured lactate level to a baseline lactate level representative of noncancerous activity, and making a determination as to whether or not the measured lactate level is potentially indicative of cancer activity in the individual. The period of time is selected to be an amount of time following the glucose administration after which metabolized lactate from cancerous cells would be present in the blood and before which the metabolized lactate would be cleared or substantial amounts of non-cancerous metabolized lactate would be present in the blood of the individual.
Resumen de: WO2026131972A1
The invention relates to a device for distributing and receiving a population of pancreatic islets heterogeneous in size, the device comprising a matrix having a first face opposite a second face, characterized in that the matrix comprises concentric channels centered on a center O, the channels have an opening for receiving the pancreatic cells, the opening leading out onto the first face, the opening extending over the entire length (L) of the channel, the opening having a width (I) taken along the section Si, the device being configured such that the widths of the opening of two adjacent channels have an equal or increasing value moving away from the center O and such that the widths of the opening of a channel closest to the center O and of a channel furthest from the center O have an increasing value moving away from the center O. The invention relates to the field of implantable devices, in particular artificial pancreas devices.
Resumen de: EP4763078A2
An example method for calibrating a glucose sensor includes determining, by one or more processors, a set of electrical parameters for the glucose sensor of a plurality of glucose sensors and determining, by the one or more processors, a cluster for the glucose sensor based on the set of electrical parameters. Each cluster of the plurality of clusters identifies respective configuration information. In this example, the method includes configuring, by the one or more processors, the glucose sensor to determine a glucose level of a patient based on configuration information identified by the determined cluster.
Resumen de: WO2025038566A1
The exemplary embodiments may provide a correction factor (CF) for a user that is dynamically adjustable based on current glucose level. In some exemplary embodiments, the CF of the user is adjusted based on the current glucose level of the user. As the current glucose level of the user increases to be above a threshold, the CF may be adjusted to reflect a decrease in the insulin sensitivity of the user. This adjustment may cause the control system to increase the amount of insulin delivered to the user as the glucose level of the user exceeds the threshold. Similarly, the CF of the user may be adjusted based on the current target glucose level of the user or based on a combination of the current glucose level of the user and the current target glucose level of the user.
Resumen de: EP4765154A2
0001 An automated closed-loop blood glucose control system comprises a continuous glucose-monitoring sensor (101), a subcutaneous insulin delivery device (103); and a controller (105) which determines a maximal allowable insulin injection amount and determines an insulin delivery control signal on the basis of the maximal allowable insulin injection amount and the quantity of insulin to inject.
Resumen de: EP4765156A1
A blood glucose management method, a user interface, and a related apparatus are provided. According to the blood glucose management method, a first meal time can be determined based on historical blood glucose values of a user; a second meal time can be determined based on one or more of the following: a meal time input by the user, a hand movement of the user, and a heart rate of the user; and a third meal time can be determined based on the first meal time and the second meal time, where the third meal time is used to evaluate a blood glucose health status of the user. A meal time of the user is predicted based on historical meal times of the user that are determined in a plurality of manners, so that an electronic device can evaluate a blood glucose status of the user more accurately.
Resumen de: US12665067B1
Methods and systems are described for a computer-implemented method for managing behavior in a subject, the method comprising: monitoring a plurality of behavioral events, each event being correlated to a timestamp within a time period; identifying a pattern in the plurality of behavioral events; generating, based on the identified pattern, personalized content for the subject; generating one or more nudges for the subject based on the personalized content, wherein the one or more nudges comprise prompts or suggestions aimed at encouraging adherence to executing suggested behavior changes provided in the personalized content; and causing presentation of the personalized content and the one or more nudges to the subject.
Resumen de: US20260144222A1
0000 The present invention provides novel snap pea cultivar Sugar 204 and plant parts, seed, and tissue culture therefrom. The invention also provides methods for producing a pea plant by crossing the pea plants of the invention with themselves or another pea plant. The invention also provides pea plants produced from such a crossing as well as plant parts, seed, and tissue culture therefrom.
Resumen de: WO2021011738A1
A glucose level control system can autonomously modify therapy provided to a subject based on a comparison of the effect of different values for a control parameter. The system can deliver therapy to the subject during a first therapy period using a first value for the control parameter and determine a corresponding first effect to the first therapy by analyzing glycemic control of blood glucose in the subject. The system may autonomously generate a second value for the control parameter, and determine a second effect corresponding to a second therapy provided during a second time period using the second value. By comparing the effects of the two therapy periods, a value for the control parameter that provides improved blood glucose level management can be determined.
Resumen de: US20260165589A1
The present disclosure relates to a non-invasive sensing system for measuring key body vitals. The system includes a sensing device to generate a pre-processed signal in response to the lights reflected by the fingertips of a user. The pre-processed signal is received by a client application for extracting features using a pre-trained artificial intelligence (AI) based model to accurately measure at least six key body vitals including blood glucose, blood sugar (HBA1C), electrocardiogram (ECG), heart rate, blood oxygen level (SPo2), blood pressure, and body temperature. The system also includes a user interface, of the client application, to receive a request for the measured key body vitals and to output the measured key body vitals.
Resumen de: WO2026123086A1
The present invention relates to a wearable device intended for the field of healthcare, more specifically for the continuous monitoring of vital signs and for the prevention of pressure ulcers, deep vein thrombosis (DVT) and pulmonary embolism (PE) in bedridden patients or patients with reduced mobility. The device comprises a garment equipped with sensors that monitor an electrocardiogram (ECG), respiratory rate, temperature, oximetry, arterial blood pressure, blood leakage, and glucose levels. A system of anatomical air pockets automatically adjusts the pressure in critical areas of the body so as to redistribute the pressure exerted on critical points susceptible to the formation of sores and on points prone to the formation of blood clots.
Resumen de: WO2026127632A1
A multi-organ model for type 2 diabetes according to the present invention comprises: a pancreatic model unit including pancreatic beta cells and a pancreatic tissue-derived decellularized extracellular matrix (PdECM); an adipose tissue model unit including adipocytes, macrophages, and a visceral adipose tissue-derived decellularized extracellular matrix (VadECM); and a liver model unit including hepatocytes and a liver tissue-derived decellularized extracellular matrix (LdECM).
Resumen de: WO2026127641A1
The bioink for printing a human adipose tissue-mimicking structure of the present invention comprises a porcine adipose-derived decellularized extracellular matrix, and provides a human inflammatory disease model and a human diabetes model, both comprising a human adipose tissue-mimicking structure produced by printing with the bioink for printing a human adipose tissue-mimicking structure.
Resumen de: US20260172935A1
0000 The present disclosure regards an electronic device for insulin delivery management. The electronic device includes an antenna and a processor. The processor is configured to operate in a first communication mode and then operate in a second communication mode responsive to determining that one or more communication criteria are satisfied. The first communication mode involves communicating via the antenna with first and second peripheral devices according to respective first and duty cycles. And the second communication mode involves communicating via the antenna with the first and second peripheral devices according to respective first and second adjusted duty cycles. The first and second duty cycles are different from the first and second adjusted duty cycles, respectively.
Resumen de: US20260165617A1
A sensor (e.g., an analyte sensor) that may be implanted partially or fully within a living animal (e.g., a human) and may be used to measure an analyte (e.g., glucose or oxygen) in a medium (e.g., interstitial fluid, blood, or intraperitoneal fluid) within the animal. The sensor may include a housing, a first polymer that includes analyte indicator molecules and covers at least a portion of the housing, and a second polymer that forms an interpenetrating network with the first polymer. The second polymer may prevent biological or protein interference of the sensor.
Resumen de: US20260167932A1
0000 A method for generating immuno-free and stress-resistant donor cells comprising editing PRDM1 and FOXP3 genes in T-cells and B-cells with CRISPR-Cas9 and modulating immune responses to reduce inflammation and prevent autoimmunity. Particularly, the present invention discloses a method for treating Type 1 Diabetes, comprising genetically modifying pancreatic beta cells with CRISPR-Cas9, and altering HLA expression, and upregulating immune checkpoint molecules such as PD-L1 to obtain immune-tolerant and stress-resistant pancreatic beta cells.
Resumen de: WO2026126865A1
The present disclosure pertains to a measurement module and a measurement system with which it is possible to achieve highly accurate measurement of glucose levels. This measurement module includes a plurality of sensors to be attached to a human body via electrodes. In the measurement module, a measurement unit inputs RF signals to at least any one of the sensors to measure reflected signals and transmitted signals, and on the basis of these measured signals, outputs glucose calculation information for calculating a glucose level in the human body. The present disclosure is applicable to wearable devices such as smartwatches.
Resumen de: US20260166220A1
0000 Embodiments disclosed herein are directed to an applicator for inserting a cannula into a body of the user for delivering medication from a medication infusion device to the user. Features of the applicator device provide a more reliable, secure and safe insertion process.
Resumen de: US20260166226A1
Presented is a medicament delivery system including a controller, a wearable medication delivery device, an analyte sensor, and other devices. In an example, a receiver is operable to receive glucose measurement values from the analyte sensor. A number of devices of the medicament delivery system may include a processor operable to execute programming code and to identify anomalous readings among the received glucose measurement values. The identified anomalous reading may, for example, be based on the received glucose measurement values violating a measurement change threshold indicative of abnormal sensor behavior. The processor may be operable to, in response to identifying the anomalous reading, revert a medicament delivery setting to a default safety basal delivery setting and/or generate a notification, an inquiry, and/or an alert for presentation to a user.
Resumen de: WO2026128361A1
Disclosed herein are methods of treating a subject having diabetes with a population of stem cell-derived islet cells and one or more immunosuppressive reagents, such as an anti-thymocyte globulin binding moiety. The subject may have received an organ transplant.
Nº publicación: US20260166221A1 18/06/2026
Solicitante:
TANDEM DIABETES CARE INC [US]
Tandem Diabetes Care, Inc.
Resumen de: US20260166221A1
Provided herein are systems and methods for delivering medication, such as insulin, that are user-friendly, environmentally-friendly, lower cost, discreet, less prone to errors, and/or that deliver precise, repeatable doses of medication, as well as accessories for applying and managing the same. In embodiments, the system includes a wearable insulin pump having a patch-style form factor for adhesion to a user's body surface.
BOPI
Sede Electrónica
